{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:42:14Z","timestamp":1792168934343,"version":"4.4.0"},"reference-count":65,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF 22-161"],"award-info":[{"award-number":["BCRF 22-161"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Florida Department of Health Bankhead Coley","award":["22B08"],"award-info":[{"award-number":["22B08"]}]},{"name":"National Institutes of Health Mayo Clinic Breast Cancer SPORE","award":["P50CA116201"],"award-info":[{"award-number":["P50CA116201"]}]},{"name":"United States Department of Defense, Breast Cancer Research Program","award":["W81XWH-15-1-0292"],"award-info":[{"award-number":["W81XWH-15-1-0292"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Tumor-infiltrating lymphocytes (TILs) are established determinants of clinical outcomes in breast cancer.\n                      <jats:sup>1\u20136<\/jats:sup>\n                      While stromal TILs (sTILs) are commonly evaluated due to easier scoring and higher interobserver reproducibility, intraepithelial TILs may provide additional insights into anti-tumor immunity.\n                      <jats:sup>7<\/jats:sup>\n                      We aimed to comprehensively characterize immunotype-associated cellular landscapes in triple-negative breast cancer (TNBC) and identify features associated with clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      212 TNBC tumors were classified into three immunotypes based on immune infiltrate location and density: immune desert (ID), immune excluded (IE), and immune inflamed (IN).\n                      <jats:sup>8<\/jats:sup>\n                      Single-cell spatial transcriptomics was performed on 75 tumors to define the cellular composition and functional states of the tumor microenvironment across immunotypes. Findings were validated and integrated with bulk RNA sequencing data and clinical outcome datasets from FinXX, CALGB-40603, I-SPY 2, and Real-World Clinico-Genomic Data (RWCGD) cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with IN tumors had significantly improved outcomes compared with ID tumors. Despite high sTILs, IE tumors showed poor outcomes similar to ID tumors. Single-cell spatial analysis revealed that ID and IE tumors exhibited reduced major histocompatibility complex I\/II expression and fewer tumor-resident plasmacytoid dendritic cells (pDCs) compared with IN tumors, which were enriched for interferon-alpha (IFN\u03b1) and interferon-gamma (IFN\u03b3) responses. High IFN response scores were associated with favorable outcomes across multiple therapy types in independent datasets. Deconvolution of RWCGD bulk RNA-seq data confirmed that pDC abundance correlated with improved outcomes specifically in hormone receptor\u2013negative subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study highlights pDCs and IFN signaling as hallmarks of effective anti-tumor immunity in TNBC. Immunotype-based profiling underscores the limited prognostic value of sTILs alone in immune-excluded tumors and supports pDCs and IFN pathways as potential biomarkers for prognosis and therapeutic development in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014020","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:15:11Z","timestamp":1780503311000},"page":"e014020","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct00114816","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00861705","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00114816","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00861705","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01042379","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-7806","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic in Florida, Jacksonville, Florida, USA"},{"name":"Department of Pioneering Science, Office of Core Shared Services, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi M","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohua","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin K","family":"Deshmukh","sequence":"additional","affiliation":[{"name":"Caris Life Sciences Inc Phoenix, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"George W","family":"Sledge","sequence":"additional","affiliation":[{"name":"Caris Life Sciences Inc Phoenix, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-5974","authenticated-orcid":false,"given":"Justin M","family":"Balko","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Kachergus","sequence":"additional","affiliation":[{"name":"Department of Pioneering Science, Office of Core Shared Services, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pioneering Science, Office of Core Shared Services, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gregory","sequence":"additional","affiliation":[{"name":"NanoString Technologies Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Gong","sequence":"additional","affiliation":[{"name":"NanoString Technologies Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Joensuu","sequence":"additional","affiliation":[{"name":"Department of Oncology, HUS Helsinki University Hospital, Helsinki, Finland"},{"name":"University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith A","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-8165","authenticated-orcid":false,"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Carey","sequence":"additional","affiliation":[{"name":"UNC School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M","family":"Sikov","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brown University Warren Alpert Medical School, Providence, Rhode Island, USA"},{"name":"Women & Infants Hospital of Rhode Island, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-4441","authenticated-orcid":false,"given":"Roberto","family":"Leon-Ferre","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9932-4467","authenticated-orcid":false,"given":"Keith L","family":"Knutson","sequence":"additional","affiliation":[{"name":"Department of Immunology, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C","family":"Boughey","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic Rochester, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N","family":"Ingle","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna R","family":"Kalari","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic Rochester, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus J","family":"Couch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan W","family":"Asmann","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Goetz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Aubrey","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Pioneering Science, Office of Core Shared Services, Mayo Clinic in Florida, Jacksonville, Florida, USA"},{"name":"Department of Cancer Biology, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranya","family":"Chumsri","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mayo Clinic in Florida, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060309150523000_14.6.e014020.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2026060309150523000_14.6.e014020.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"2026060309150523000_14.6.e014020.3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.189"},{"key":"2026060309150523000_14.6.e014020.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3245"},{"key":"2026060309150523000_14.6.e014020.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02119-4"},{"key":"2026060309150523000_14.6.e014020.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056"},{"key":"2026060309150523000_14.6.e014020.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450"},{"key":"2026060309150523000_14.6.e014020.8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01010"},{"key":"2026060309150523000_14.6.e014020.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2026060309150523000_14.6.e014020.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz395"},{"key":"2026060309150523000_14.6.e014020.11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30904-x"},{"key":"2026060309150523000_14.6.e014020.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7370"},{"key":"2026060309150523000_14.6.e014020.13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-023-07233-2","article-title":"High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy","volume":"205","author":"Wood","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2026060309150523000_14.6.e014020.14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026060309150523000_14.6.e014020.15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jama.2024.10483","article-title":"Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer-Reply","volume":"332","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"2026060309150523000_14.6.e014020.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-023-00580-2"},{"key":"2026060309150523000_14.6.e014020.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011"},{"key":"2026060309150523000_14.6.e014020.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"2026060309150523000_14.6.e014020.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa6204"},{"key":"2026060309150523000_14.6.e014020.20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature New Biol"},{"key":"2026060309150523000_14.6.e014020.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"key":"2026060309150523000_14.6.e014020.22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature New Biol"},{"key":"2026060309150523000_14.6.e014020.23","doi-asserted-by":"crossref","DOI":"10.3390\/biom14020171","article-title":"Defining Melanoma Immune Biomarkers-Desert, Excluded, and Inflamed Subtypes-Using a Gene Expression Classifier Reflecting Intratumoral Immune Response and Stromal Patterns","volume":"14","author":"Mlynska","year":"2024","journal-title":"Biomolecules"},{"key":"2026060309150523000_14.6.e014020.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2026060309150523000_14.6.e014020.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008185","article-title":"Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials","volume":"12","author":"Roller","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026060309150523000_14.6.e014020.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0343"},{"key":"2026060309150523000_14.6.e014020.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37806-0","article-title":"Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer","volume":"14","author":"Carter","year":"2023","journal-title":"Nat Commun"},{"key":"2026060309150523000_14.6.e014020.28","doi-asserted-by":"crossref","DOI":"10.3390\/v15051198","article-title":"Efficiency of Interferon-\u03b3 in Activating Dendritic Cells and Its Potential Synergy with Toll-like Receptor Agonists","volume":"15","author":"Bian","year":"2023","journal-title":"Viruses"},{"key":"2026060309150523000_14.6.e014020.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.10.020"},{"key":"2026060309150523000_14.6.e014020.30","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22339","article-title":"The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone","volume":"2","author":"Slaney","year":"2013","journal-title":"Oncoimmunology"},{"key":"2026060309150523000_14.6.e014020.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01167-5"},{"key":"2026060309150523000_14.6.e014020.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.08.001"},{"key":"2026060309150523000_14.6.e014020.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4499-7"},{"key":"2026060309150523000_14.6.e014020.34","unstructured":"liuyi901 . pDC_JITC. GitHub. Available: https:\/\/github.com\/liuyi901\/pDC_JITC"},{"key":"2026060309150523000_14.6.e014020.35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jamaoncol.2016.6120","article-title":"Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial","volume":"3","author":"Joensuu","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026060309150523000_14.6.e014020.36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature24993","article-title":"Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours","volume":"552","author":"Milner","year":"2017","journal-title":"Nature New Biol"},{"key":"2026060309150523000_14.6.e014020.37","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm9409","article-title":"Human dendritic cells in cancer","volume":"7","author":"Kvedaraite","year":"2022","journal-title":"Sci Immunol"},{"key":"2026060309150523000_14.6.e014020.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.027"},{"key":"2026060309150523000_14.6.e014020.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00741-5"},{"key":"2026060309150523000_14.6.e014020.40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040470","article-title":"Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review","volume":"11","author":"Kouck\u00fd","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026060309150523000_14.6.e014020.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1945"},{"key":"2026060309150523000_14.6.e014020.42","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-019-00334-2"},{"key":"2026060309150523000_14.6.e014020.43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.21.02054","article-title":"Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial","volume":"40","author":"Joensuu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060309150523000_14.6.e014020.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01506"},{"key":"2026060309150523000_14.6.e014020.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.011"},{"key":"2026060309150523000_14.6.e014020.46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.2021.39.15_suppl.1006","article-title":"The tumor microenvironment (TME) and atezolizumab + nab -paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130","volume":"39","author":"Emens","year":"2021","journal-title":"JCO"},{"key":"2026060309150523000_14.6.e014020.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.09.006"},{"key":"2026060309150523000_14.6.e014020.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481"},{"key":"2026060309150523000_14.6.e014020.49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41586-023-06132-2","article-title":"In situ tumour arrays reveal early environmental control of cancer immunity","volume":"618","author":"Ortiz-Mu\u00f1oz","year":"2023","journal-title":"Nature New Biol"},{"key":"2026060309150523000_14.6.e014020.50","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2026060309150523000_14.6.e014020.51","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1139","article-title":"Plasmacytoid dendritic cell biology and its role in immune-mediated diseases","volume":"9","author":"Ye","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"2026060309150523000_14.6.e014020.52","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3058"},{"key":"2026060309150523000_14.6.e014020.53","doi-asserted-by":"publisher","DOI":"10.1002\/path.1344"},{"key":"2026060309150523000_14.6.e014020.54","first-page":"6478","article-title":"Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer","volume":"63","author":"Hartmann","year":"2003","journal-title":"Cancer Res"},{"key":"2026060309150523000_14.6.e014020.55","doi-asserted-by":"publisher","DOI":"10.1038\/nm1201-1339"},{"key":"2026060309150523000_14.6.e014020.56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113342","article-title":"Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC)","volume":"12","author":"Oshi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026060309150523000_14.6.e014020.57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612826113"},{"key":"2026060309150523000_14.6.e014020.58","doi-asserted-by":"publisher","DOI":"10.1038\/S41587-022-01483-Z"},{"key":"2026060309150523000_14.6.e014020.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-020-01018-x"},{"key":"2026060309150523000_14.6.e014020.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01094-0"},{"key":"2026060309150523000_14.6.e014020.61","doi-asserted-by":"crossref","unstructured":"Danaher P , Zhao E , Yang Z , et al . Insitutype: likelihood-based cell typing for single cell spatial transcriptomics. Bioinformatics [Preprint] 2022. doi:10.1101\/2022.10.19.512902","DOI":"10.1101\/2022.10.19.512902"},{"key":"2026060309150523000_14.6.e014020.62","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/asv013"},{"key":"2026060309150523000_14.6.e014020.63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS ONE"},{"key":"2026060309150523000_14.6.e014020.64","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4197"},{"key":"2026060309150523000_14.6.e014020.65","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann Statist"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:15:16Z","timestamp":1780503316000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2025-014020"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014020","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}